PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34389380-8	2021	Molecular modeling experiments revealed N501Y-specific stacking interactions in the RBD-ACE2 complex and provided insight into EGCG interference with the complex formation.	epigallocatechin gallate	127-131	angiotensin converting enzyme 2	Homo sapiens	88-92	
34815622-4	2022	Epigallocatechin-3-gallate - a polyphenol from tea - effectively has been shown to inhibit the activity of SARS-CoV-2 as it blocked binding of coronavirus 2 to human angiotensin converting enzyme 2, decreased the expression of inflammatory factors in the blood, including tumor necrosis factor-alpha and interleukin-6, and significantly increased the overall fertilization efficiency in animals.	epigallocatechin gallate	0-26	angiotensin converting enzyme 2	Homo sapiens	166-197	
34461999-0	2021	Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor.	epigallocatechin gallate	0-24	angiotensin converting enzyme 2	Homo sapiens	131-135	
34461999-8	2021	Mechanistic studies revealed that EGCG blocked infection at the entry step through interfering with the engagement of the receptor binding domain (RBD) of the viral spikes to angiotensin-converting enzyme 2 (ACE2) receptor of the host cells.	epigallocatechin gallate	34-38	angiotensin converting enzyme 2	Homo sapiens	175-206	
34461999-8	2021	Mechanistic studies revealed that EGCG blocked infection at the entry step through interfering with the engagement of the receptor binding domain (RBD) of the viral spikes to angiotensin-converting enzyme 2 (ACE2) receptor of the host cells.	epigallocatechin gallate	34-38	angiotensin converting enzyme 2	Homo sapiens	208-212	
33746069-7	2021	Nigellidine effectively binds in the Angiotensin- II binding-site/entry-pocket (-7.54 kcal/mol, -211.76, Atomic-Contact-Energy; ACE-value) of ACE2 (Ki 8.68 and 8.3 mumol) in comparison to known-binder EGCG (-4.53) and Theaflavin-di-gallate (-2.85).	epigallocatechin gallate	201-205	angiotensin converting enzyme 2	Homo sapiens	142-146	
34403732-7	2021	Interestingly, EGCG, Bkc and Ibvc bind to ACE2 receptor in BLI assay, suggesting a dual binding to RBD and ACE2.	epigallocatechin gallate	15-19	angiotensin converting enzyme 2	Homo sapiens	42-46	
34403732-7	2021	Interestingly, EGCG, Bkc and Ibvc bind to ACE2 receptor in BLI assay, suggesting a dual binding to RBD and ACE2.	epigallocatechin gallate	15-19	angiotensin converting enzyme 2	Homo sapiens	107-111	
34243689-8	2021	Affinity of phytoconstituents towards SARS-CoV-2 spike protein-human ACE2 complex decreased as isomeldenin > tinosporaside > EGCG whereas in case of unbound ACE2, the strength of binding followed the order isomeldenin > tinosporaside > ellagic acid.	epigallocatechin gallate	125-129	angiotensin converting enzyme 2	Homo sapiens	69-73	
34208050-5	2021	EGCG, TSA, and TFDG significantly inhibited interaction between recombinant ACE2 and RBD of S protein.	epigallocatechin gallate	0-4	angiotensin converting enzyme 2	Homo sapiens	76-80	
35382132-8	2022	Conclusion: EGCG can be a potential inhibitor drug which can bind with ACE-2 receptor thus inhibiting the interaction of mainly Mpro protein and spike glycoprotein of SARS-CoV-2.	epigallocatechin gallate	12-16	angiotensin converting enzyme 2	Homo sapiens	71-76	
35475273-8	2022	Conclusion: EGCG can be a potential inhibitor drug which can bind with ACE-2 receptor thus inhibiting the interaction of mainly Mpro protein and spike glycoprotein of SARS-CoV-2.	epigallocatechin gallate	12-16	angiotensin converting enzyme 2	Homo sapiens	71-76	
34054222-4	2021	Key findings and conclusions: EGCG, via activating Nrf2, can suppress ACE2 (a cellular receptor for SARS-CoV-2) and TMPRSS2, which mediate cell entry of the virus.	epigallocatechin gallate	30-34	angiotensin converting enzyme 2	Homo sapiens	70-74